补髓生血颗粒对慢性再生障碍性贫血患者骨髓单个核细胞粘附分子VLA-6/CD49f水平影响的研究

目的：探讨补髓生血颗粒对慢性再生障碍性贫血（简称慢性再障,ChronicAplasticAnemiaCAA）患者的整合素VLA亚家族粘附分子VLA-6/CD49f表达水平的影响。方法：将45例慢性再障患者随机分为补髓生血颗粒组（试验组）和再障生血片组（对照组）,采用流式细胞术（FCM）检测试验组和对照组慢性再障患者治疗前后骨髓单个核细胞相关整合素VLA亚家族粘附分子VLA-6/CD49f的抗原表达水平并进行比较分析,并与10例正常人进行比较。结果：CAA患者骨髓单个核细胞粘附分子VLA-6/CD49f处于低表达状态,疗后表达水平升高,且补髓生血颗粒对VLA-6/CD49f表达的调整程度优于再障生血片组,且肾阳虚与肾阴虚患者疗后VLA-5/CD49f表达有显著差异。结论：慢性再障患者骨髓单个核细胞粘附分子VLA-6/CD49f表达水平异常,它可能参与了CAA的造血调控,补髓生血颗粒可以通过调节骨髓细胞粘附分子表达水平来改善CAA的骨髓造血功能,是治疗CAA的有效药物。

Effects of Marrow- supplementing and Blood - engendering Granule on vla - 6/cd49f in patients of chronic aplastic anemia

Objective:To Observe the expression level of VLA-6/ CD49f in CAA patients before and after treatment by marrow-supplementing and blood-engendering granule (MSABE).Method:Forty-five cases of CAA were divided into two groups randomly-twenty-five patients of the treating group were treated with MSABE and twenty of the control group were treated with Zaizhang Shengxue tablet (ZZSXT). We explored flow cytometry (FCM) to detect forty-five patients the expression of related adhesion moleculesVLA-6/CD49f on hematopoietic stem and progenitor cell (HSPC) before and after treatment.Result:The levels of VLA-6/CD49f was lower than that in the normal controlled group before treatment, but after treatment it got elevated. The enhancement in experimental group was superior to that in control group, and the advancement in Yang deficiency group was superior to that in Yin deficiency group. Conclusion:There was abnormal expression of bone marrow VLA-6/ CD49f in CAA patients. MSABE can adjust the expression level of marrow mononuclear cell to improve hematopoiesis in bone marrow. MSABE is an effective drug to treat CAA, and is worthy of further study and development.